United Therapeutics UTHR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $781.5M-1.6% | $790.2M+7.4% | $799.5M+6.8% | $798.6M+11.7% | $794.4M+17.2% | ||
| $133.4M+44.2% | $103.4M+36.2% | $100.9M+21.4% | $87.6M+12.6% | $92.5M+26.9% | ||
| $648.1M-7.7% | $686.8M+4.1% | $698.6M+4.9% | $711M+11.6% | $701.9M+16.1% | ||
| 82.9%-5.4pp | 86.9%-2.8pp | 87.4%-1.5pp | 89%-0.1pp | 88.4%-0.9pp | ||
| $138.2M-7.2% | $139.5M+4.3% | $127.5M+23.2% | $134M-4.0% | $149M+43.1% | ||
| $184.1M+8.2% | $190.6M+13.1% | $182.6M-16.7% | $212.5M+19.7% | $170.1M+17.8% | ||
| $455.7M+10.7% | $433.5M+14.6% | $411M+1.3% | $434.1M+9.9% | $411.6M+28.1% | ||
| $325.8M-14.9% | $356.7M-0.3% | $388.5M+13.2% | $364.5M+13.9% | $382.8M+7.4% | ||
| 41.7%-6.5pp | 45.1%-3.5pp | 48.6%+2.8pp | 45.6%+0.9pp | 48.2%-4.4pp | ||
| $3M-50.8% | $3.1M-60.8% | $3M-70.3% | $7.3M-37.1% | $6.1M-54.1% | ||
| $41.8M-18.2% | $43.2M-12.4% | $46.4M-6.8% | $51.3M+11.0% | $51.1M-5.0% | ||
| -$7.5M-118% | $87.3M+125% | $49.5M+8.8% | $43.9M+24.0% | $40.7M-3.8% | ||
| $318.3M-24.8% | $444M+12.0% | $438M+12.7% | $408.4M+14.9% | $423.5M+6.2% | ||
| $43.4M-57.2% | $79.7M-16.3% | $99.3M+24.9% | $98.9M+28.1% | $101.3M+10.1% | ||
| $274.9M-14.7% | $364.3M+20.9% | $338.7M+9.6% | $309.5M+11.3% | $322.2M+5.1% | ||
| 35.2%-5.4pp | 46.1%+5.2pp | 42.4%+1.1pp | 38.8%-0.1pp | 40.6%-4.7pp | ||
| $5.82-12.2% | $7.69+23.8% | $7.16+12.1% | $6.41+9.6% | $6.63+7.5% | ||
| $6.32-12.0% | $8.37+24.7% | $7.73+11.5% | $6.86+9.6% | $7.18+10.1% | ||
| 47.2M-2.9% | 47.9M-1.2% | 47.3M-2.3% | 48.3M+1.7% | 48.6M-2.2% | ||
| 43.5M-3.1% | 44.3M-2.0% | 43.8M-1.8% | 45.1M+1.6% | 44.9M-4.5% | ||
| -$46.3M-977% | $47.2M— | $6.1M+5.2% | -$100K-113% | -$4.3M-339% | ||
| $781.5M-1.6% | $790.2M+7.4% | $799.5M+6.8% | $798.6M+11.7% | $794.4M+17.2% | ||
| $348.4M-13.5% | $379.5M+0.6% | $410.4M+13.3% | $385.6M+13.9% | $402.6M+8.4% | ||
| 44.6%-6.1pp | 48%-3.3pp | 51.3%+3.0pp | 48.3%+0.9pp | 50.7%-4.1pp | ||
| $325.8M-14.9% | $356.7M-0.3% | $388.5M+13.2% | $364.5M+13.9% | $382.8M+7.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is United Therapeutics's revenue?
- United Therapeutics (UTHR) generated $3.2B in revenue over the trailing twelve months, up 5.9% year over year.
- Is United Therapeutics profitable?
- United Therapeutics reported $1.3B in net income over the trailing twelve months, a 40.6% net margin.
- What are United Therapeutics's profit margins?
- Gross margin is 86.6% and operating margin is 45.3%, with a 40.6% net margin.
- What is United Therapeutics's earnings per share?
- United Therapeutics's diluted EPS over the trailing twelve months is $27.08.
- Where does United Therapeutics's income statement data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
